Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 17;155(5):249-257.
doi: 10.1177/17151635221114114. eCollection 2022 Sep-Oct.

Deprescribing practices in Canada: A scoping review

Mansi Desai, Tanya Park

Deprescribing practices in Canada: A scoping review

Mansi Desai et al. Can Pharm J (Ott). .

Abstract

Background: Excessive and inappropriate use of medications, defined as polypharmacy, can increase the risk of adverse drug reactions while affecting patient adherence and quality of life. Therefore, optimizing pharmacotherapies through deprescribing practices plays a crucial role in managing chronic conditions, avoiding adverse effects and improving patient outcomes. The purpose of this study was to explore research initiatives surrounding deprescribing in Canada.

Methods: A scoping review was conducted that involved a search of 6 databases. Studies that highlighted deprescribing interventions, experiences and other effects on Canadian populations were included.

Results: Searches yielded 2327 citations, of which 31 were included in this review. Five major themes and ideas were identified: deprescribing targeted medications, financial effects of deprescribing, deprescribing in special populations, insight from health care providers and deprescribing frameworks.

Conclusion: Deprescribing practices in Canada have shown a wide range of beneficial results across various health care settings, populations and medication classes and have the potential to reduce medication-related harm in all Canadian health care settings.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Modified PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) flowchart
See this image and copyright information in PMC

References

    1. Polypharmacy part 1 . Pitfalls of multiple medications: taking multiple drugs and risk of interactions. 2020. Available: https://www.mcmasteroptimalaging.org/blog/detail/blog/2014/03/29/are-you... (accessed June 1, 2020).
    1. Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17:230. - PMC - PubMed
    1. Wise J. Polypharmacy: a necessary evil. BMJ 2013;347:f7033. - PubMed
    1. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore) 2010;89(5):295-299. - PubMed
    1. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997;315(7115):1096-9. - PMC - PubMed

Publication types